TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02367456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913 (Glasdegib)
Description: Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913 (Glasdegib)
Description: Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
Study: NCT01972659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
Study: NCT02809300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood collection
Study: NCT01886014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02111148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urea and creatinine
Description: the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
Study: NCT01972659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate
Description: Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion
Study: NCT02111148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nitrazine
Description: Nitrazine detection in vaginal wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5ml saline
Description: the vagina will be washed with 5ml saline and vaginal wash will be collected.
Study: NCT03172533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol 0.03mg and dienogest 2 mg (combination)
Description: approved oral contraceptive (Germany): Maxim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo
Study: NCT05054400

Intervention type: DRUG
Group type: OTHER
Intervention: F18 Fluciclovine
Description: Given by IV

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care
Study: NCT01972659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: 4 mg/kg iv bolus at the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: 4 mg/kg iv bolus at the end of the surgery
Study: NCT01799902

Intervention type: DRUG
Intervention: Solifenacin
Description: Oral
Study: NCT04389060

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Two capsule grape seed extract (total 600 mg)
Study: NCT04846491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study: NCT01233050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol
Description: Preoperative skin antisepsis preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine Povacrylex/74% Isopropyl Alcohol
Description: preoperative skin antisepsis preparation
Study: NCT04674332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting insulin
Description: long acting insulin analogue once daily at bed time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multiple dose regimen
Description: intermediate and short acting insulin
Study: NCT03142646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
Study: NCT04168619

Intervention type: DRUG
Intervention: Discontinue methotrexate
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.

Intervention type: DRUG
Intervention: Discontinue methotrexate
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.

Intervention type: DRUG
Intervention: Discontinue methotrexate
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.

Intervention type: OTHER
Intervention: Medication depends on clinical judgement
Description: Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
Study: NCT02724774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships®
Description: PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting.
Study: NCT00363116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: daclizumab 1 mg/kg/dose every 14 days for 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: daclizumab 1 mg/kg/dose every 14 days for 5 doses
Study: NCT04389060

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape seed extract
Description: Two capsule grape seed extract (total 600 mg)
Study: NCT01358734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
Study: NCT00904826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months.
Study: NCT03689725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
Study: NCT00045682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV
Study: NCT00226681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Telephone Support Protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT00363116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: daclizumab 1 mg/kg/dose every 14 days for 5 doses
Study: NCT00698191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic MSC (AlloMSC)
Description: Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight
Study: NCT00088582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230), Octreotide (Sandostatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230), Octreotide (Sandostatin)
Study: NCT02973841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono-ease device
Description: insertion of US guided IJV using sono-ease device
Study: NCT04427787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered orally at a dose of 60 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide will be administrated 120 mg injection every 28 days
Study: NCT02399813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac
Study: NCT01358734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support
Study: NCT03147677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Study: NCT01263977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picco- thermodilution catheter
Description: Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picco- thermodilution catheter
Description: Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
Study: NCT01539083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100 mg tablet, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100 mg tablet, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 50 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 50 mg orally.
Study: NCT03546062

Intervention type: OTHER
Intervention: patients treated by HTx
Description: From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.

Intervention type: OTHER
Intervention: patients treated by HTx
Description: From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.

Intervention type: OTHER
Intervention: patients treated by HTx
Description: From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
Study: NCT04773756

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 MG/ Daclatasvir 60mg
Description: Giving these two drugs for treatment of COVID patients
Study: NCT01828736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV: AUC 5 on Day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV: AUC 5 on Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV, 70 mg/m² BSA on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV, 70 mg/m² BSA on day 1 every 21 days
Study: NCT02130297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
Study: NCT02987556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Collection of glucose data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Collection of glucose data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Insulin Pump
Description: insulin delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Insulin Pump
Description: insulin delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemdecine
Description: Remote follow up by care health providers team

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Diabeloop Software (Model predictive control)
Description: Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
Study: NCT02384161

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isometric exercise Intermittent
Description: Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise Intermittent
Description: Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
Study: NCT02256748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT02384161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise Intermittent
Description: Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
Study: NCT03506789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 24 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 24 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Isotonic saline
Study: NCT02698046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 200mg of ferrous sulfate three times a day for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo starch
Description: 200mg of placebo starch three times a day for 4 months
Study: NCT01866774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin level
Study: NCT03748693

Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Surgery performed on women with a variety of gynecological indications

Intervention type: PROCEDURE
Intervention: Colporrhaphy
Description: Surgery performed on women with POP
Study: NCT03817879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VivaSight double-lumen tube for single-lung ventilation
Description: Procedure using a tube with a camera

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional double-lument tube for single-lung ventilation
Description: Procedure using a tube without a camera
Study: NCT02681783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
Study: NCT04223271

Intervention type: DIAGNOSTIC_TEST
Intervention: Indicor
Description: Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.